Calidi Biotherapeutics Inc. Unveils New Presentation on Advancements in Genetic Medicine Targeting Cancer and Complex Diseases

Reuters08-30

<a href="https://laohu8.com/S/CLDWW">Calidi Biotherapeutics Inc.</a> Unveils New Presentation on Advancements in Genetic Medicine Targeting Cancer and Complex Diseases

Calidi Biotherapeutics Inc. has released a corporate presentation detailing advancements in their genetic medicine technology. The company is focused on delivering precise genetic treatments for a variety of complex diseases, including cancer. Their pipeline includes several candidates at various stages of development, such as NeuroNova for glioblastoma and SuperNova for solid tumors. Calidi's innovative approach involves using stem cells loaded with viruses to enhance tumor targeting and protection from immune clearance. Additionally, the RedTail platform employs extracellular enveloped viruses for efficient dissemination. Calidi is also exploring opportunities for non-dilutive grant funding to support their intratumoral approach. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2563077162?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-30 05:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2563077162","market":"us","top_or_hot":-1,"title":"Calidi Biotherapeutics Inc. Unveils New Presentation on Advancements in Genetic Medicine Targeting Cancer and Complex Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CLDWW\">Calidi Biotherapeutics Inc.</a> Unveils New Presentation on Advancements in Genetic Medicine Targeting Cancer and Complex Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CLDI\">Calidi Biotherapeutics</a> Inc. has released a corporate presentation detailing advancements in their genetic medicine technology. The company is focused on delivering precise genetic treatments for a variety of complex diseases, including cancer. Their pipeline includes several candidates at various stages of development, such as NeuroNova for glioblastoma and SuperNova for solid tumors. Calidi's innovative approach involves using stem cells loaded with viruses to enhance tumor targeting and protection from immune clearance. Additionally, the RedTail platform employs extracellular enveloped viruses for efficient dissemination. Calidi is also exploring opportunities for non-dilutive grant funding to support their intratumoral approach. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Calidi Biotherapeutics Inc. Unveils New Presentation on Advancements in Genetic Medicine Targeting Cancer and Complex Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCalidi Biotherapeutics Inc. Unveils New Presentation on Advancements in Genetic Medicine Targeting Cancer and Complex Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-30 05:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CLDWW\">Calidi Biotherapeutics Inc.</a> Unveils New Presentation on Advancements in Genetic Medicine Targeting Cancer and Complex Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CLDI\">Calidi Biotherapeutics</a> Inc. has released a corporate presentation detailing advancements in their genetic medicine technology. The company is focused on delivering precise genetic treatments for a variety of complex diseases, including cancer. Their pipeline includes several candidates at various stages of development, such as NeuroNova for glioblastoma and SuperNova for solid tumors. Calidi's innovative approach involves using stem cells loaded with viruses to enhance tumor targeting and protection from immune clearance. Additionally, the RedTail platform employs extracellular enveloped viruses for efficient dissemination. Calidi is also exploring opportunities for non-dilutive grant funding to support their intratumoral approach. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL5SW53G:1","article_id":"2563077162","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2563077162","pubTimestamp":1756504389,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Calidi Biotherapeutics Inc. Unveils New Presentation on Advancements in Genetic Medicine Targeting Cancer and Complex Diseases. Calidi Biotherapeutics Inc. has released a corporate presentation detailing advancements in their genetic medicine technology. The company is focused on delivering precise genetic treatments for a variety of complex diseases, including cancer. Their pipeline includes several candidates at various stages of development, such as NeuroNova for glioblastoma and SuperNova for solid tumors. Calidi's innovative approach involves using stem cells loaded with viruses to enhance tumor targeting and protection from immune clearance. Additionally, the RedTail platform employs extracellular enveloped viruses for efficient dissemination. Calidi is also exploring opportunities for non-dilutive grant funding to support their intratumoral approach. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CLDI":"CALIDI BIOTHERAPEUTICS INC"},"translate_title":"Calidi Biotherapeutics Inc.推出针对癌症和复杂疾病的基因医学进展的新演示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLDI":0.9},"content_text":"Calidi Biotherapeutics Inc. Unveils New Presentation on Advancements in Genetic Medicine Targeting Cancer and Complex Diseases\n    \n\nCalidi Biotherapeutics Inc. has released a corporate presentation detailing advancements in their genetic medicine technology. The company is focused on delivering precise genetic treatments for a variety of complex diseases, including cancer. Their pipeline includes several candidates at various stages of development, such as NeuroNova for glioblastoma and SuperNova for solid tumors. Calidi's innovative approach involves using stem cells loaded with viruses to enhance tumor targeting and protection from immune clearance. Additionally, the RedTail platform employs extracellular enveloped viruses for efficient dissemination. Calidi is also exploring opportunities for non-dilutive grant funding to support their intratumoral approach. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2563077162","isCrawlerRequest":true}